Publications by authors named "Moises Diago"

Claim this Profile
D
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic dysfunction-associated Steatotic Liver Disease in Clinical Practice.
Antonio Olveira, Javier Crespo, Luis Ibañez-Samaniego, Rocío Gallego-Durán, Jose Luis Calleja, Moisés Diago

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current characteristics of patients with hepatitis C virus: results from an automated alert system.
Carlos Alventosa Mateu, María Dolores Ocete Mochón, Juan José Urquijo Ponce, Mercedes Latorre Sánchez, Inmaculada Castelló Miralles, Moisés Diago

Rev Esp Enferm Dig· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing Hepatitis Delta in Spain and the gaps in its management.
Sergio Rodríguez-Tajes, Adriana Palom, Álvaro Giráldez-Gallego, Antonio Moreno, Juan José Urquijo, Moisés Diago

Gastroenterol Hepatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reassessing HIV Detection Strategies: An Analysis of Opportunistic Screening vs. Indicator-Condition-Driven Diagnosis in Valencia, Spain.
Enrique Ortega, María Dolores Ocete, María Martínez-Roma, Concepción Gimeno, Neus Gómez, Moisés Diago

J Community Health· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
Javier Ampuero, Rocío Aller, Rocío Gallego-Durán, Javier Crespo, Jose Luis Calleja, Moisés Diago

J Gastroenterol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Juan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, Adolfo Gallego Moya, Isabel Conde Amiel, Moises Diago

Aliment Pharmacol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease.
Zobair M Younossi, Saleh A AlQahtani, Jesús Funuyet-Salas, Manuel Romero-Gómez, Yusuf Yilmaz, Moises Diago

JHEP Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
Juan Jose Urquijo-Ponce, Carlos Alventosa-Mateu, Mercedes Latorre-Sánchez, Inmaculada Castelló-Miralles, Moisés Diago

World J Gastroenterol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrarenal fibrillary glomerulonephritis as an unknown etiology of advanced liver disease.
Carlos Alventosa Mateu, Ana Vilar Gimeno, Irene Pérez Álvarez, Javier Carbonell Zamorano, Inmaculada Castelló Miralles, Moisés Diago

Gastroenterol Hepatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
Zobair M Younossi, Saleh A Alqahtani, Khalid Alswat, Yusuf Yilmaz, Caglayan Keklikkiran, Moises Diago

J Hepatol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of abnormal liver function test for hospitalized patients with COVID-19.
Carlos Alventosa Mateu, Salvador Benlloch, Moisés Diago

Gastroenterol Hepatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B virus reactivation after ibrutinib treatment.
Carlos Alventosa Mateu, Juan José Urquijo Ponce, Armando Mena Durán, Mercedes Latorre Sánchez, Inmaculada Castelló Miralles, Moisés Diago

Rev Esp Enferm Dig· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B.
Beatriz Mateos-Muñoz, María Buti, Inmaculada Fernández Vázquez, Marta Hernández Conde, Vanesa Bernal-Monterde, Moisés Diago

Dig Dis Sci· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia.
Marta Alonso-Peña, Ricardo Espinosa-Escudero, Elisa Herraez, Oscar Briz, Maria Luisa Cagigal, Moises Diago

Hepatology· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease.
Zobair M Younossi, Janus P Ong, Hirokazu Takahashi, Yusuf Yilmaz, Yuichiro Eguc Hi, Moisés Diago

Clin Gastroenterol Hepatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
Anna Reig, Carmen Álvarez-Navascués, Mercedes Vergara, Elena Gómez-Domínguez, Adolfo Gallego-Moya, Moises Diago

Am J Gastroenterol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Javier Ampuero, Rocío Aller, Rocío Gallego-Durán, Javier Crespo, Javier Abad, Moisés Diago

Liver Int· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).
Javier Ampuero, Rocío Aller, Rocío Gallego-Durán, Javier Crespo, José Luis Calleja, Moisés Diago

J Hepatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
Javier Ampuero, Rocío Aller, Rocío Gallego-Durán, Javier Crespo, José Luis Calleja, Moisés Diago

J Hepatol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.
Qian Chen, Celia Perales, María Eugenia Soria, Damir García-Cehic, Josep Gregori, Moisés Diago

Antiviral Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Javier Ampuero, Raluca Pais, Rocío Aller, Rocío Gallego-Durán, Javier Crespo, Moisés Diago

Clin Gastroenterol Hepatol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH.
Ramón Bataller, Joaquín Cabezas, Rocío Aller, Meritxell Ventura-Cots, Javier Abad, Moisés Diago

Gastroenterol Hepatol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Jordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, Moisés Diago, Alba Cachero

J Hepatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic impact of health resource optimisation in the approach to patients with hepatitis C.
Juan Turnes, Federico García, Moisés Diago, Raúl J Andrade, Pilar Díaz

Gastroenterol Hepatol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.
Emilio Suárez, María Buti, Manuel Rodríguez, Martín Prieto, Juan M Pascasio-Acevedo, Moisés Diago

Eur J Gastroenterol Hepatol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis